AXSM Maintains Buy Rating by Truist Securities -- Price Target Raised to $285

gurufocus.com · 2026-09-23

Axsome Therapeutics (AXSM) Analyst Rating Update On October 3, 2023, Truist Securities maintained a Buy rating for Axsome Therapeutics (AXSM) while raising t

Read the full story at gurufocus.com →